Siddharth Taparia’s Strategy for Transforming Globally Fragmented JLL Into a Unified Marketing ForceSeptember 17, 2026
Accounting With just $6K left, Nymox Pharmaceutical (NYMXF) discloses doubt it can keep operatingBy AdminBitSeptember 15, 20260 NYMXF remains a pre‑revenue biotech with heavy losses, severe liquidity constraints, going‑concern uncertainty and key NX‑1207 regulatory decisions still pending.
